Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled cannabidiol for bronchiolitis obliterans syndrome after allogeneic bone marrow transplantation
MOH_2022-04-03_010713Phase 2Not yet recruiting
- Sponsor
- ד"ר משה ישורון
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cannabidiol in Bronchiolitis Obliterans Syndrome (BOS) and chronic graft-versus-host disease (cGVHD) (3 arms), sponsored by ד"ר משה ישורון. Primary endpoint: Safety and tolerability. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on MOH_2022-04-03_010713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-04-03_010713.